No survival benefit with empirical vancomycin therapy for coagulase-negative staphylococcal bloodstream infections in infants.
about
Prevention and treatment of neonatal nosocomial infections.Adverse consequences of neonatal antibiotic exposureHeart rate characteristic index monitoring for bloodstream infection in an NICU: a 3-year experience.Appropriate Use of Vancomycin in NICU Despite Free-for-All PolicyGram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.Empiric antibiotic regimens for neonatal sepsis in Australian and New Zealand neonatal intensive care units.
P2860
No survival benefit with empirical vancomycin therapy for coagulase-negative staphylococcal bloodstream infections in infants.
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
No survival benefit with empir ...... dstream infections in infants.
@ast
No survival benefit with empir ...... dstream infections in infants.
@en
type
label
No survival benefit with empir ...... dstream infections in infants.
@ast
No survival benefit with empir ...... dstream infections in infants.
@en
prefLabel
No survival benefit with empir ...... dstream infections in infants.
@ast
No survival benefit with empir ...... dstream infections in infants.
@en
P2093
P2860
P1476
No survival benefit with empir ...... dstream infections in infants.
@en
P2093
Antibacterial Resistance Leadership Group
Christoph P Hornik
Daniel K Benjamin
Heather R Cross
Jessica E Ericson
Joshua Thaden
Michael Cohen-Wolkowiez
P Brian Smith
P2860
P304
P356
10.1097/INF.0000000000000573
P577
2015-04-01T00:00:00Z